Chemistry:Regadenoson
 | |
| Clinical data | |
|---|---|
| Trade names | Lexiscan, Rapiscan |
| Other names | CVT-3146, 1-[6-amino-9-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]purin-2-yl]- N-methylpyrazole-4-carboxamide |
| AHFS/Drugs.com | Monograph |
| License data |
|
| Routes of administration | Intravenous |
| ATC code | |
| Legal status | |
| Legal status |
|
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| IUPHAR/BPS | |
| DrugBank | |
| ChemSpider | |
| UNII | |
| KEGG | |
| ChEMBL | |
| Chemical and physical data | |
| Formula | C15H18N8O5 |
| Molar mass | 390.360 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
  (what is this?) (verify) | |
Regadenoson, sold under the brand name Lexiscan among others, is an A2A adenosine receptor agonist that is a coronary vasodilator that is commonly used in pharmacologic stress testing. It produces hyperemia quickly and maintains it for a duration that is useful for radionuclide myocardial perfusion imaging.[1] The selective nature of the drug makes it preferable to other stress agents such as adenosine, which are less selective and therefore cause more side-effects.
Regadenoson was approved by the United States Food and Drug Administration on April 10, 2008, and is marketed by Astellas Pharma under the tradename Lexiscan.[2] It is approved for use in the European Union and under the name of Rapiscan. It is marketed by GE Healthcare and is sold in both the United Kingdom and Germany. Regadenoson was approved for use in the European Union in September 2010.[3] It is available as a generic medication.[4]
Regadenoson has a two- to three-minute biological half-life, as compared with adenosine's ten-second half-life. As a result, regadenoson stress protocols use a single bolus, instead of the four- to six-minute continuous infusion that was needed with adenosine. Whereas the adenosine infusion is weight based (140 mcg/kg/minute), regadenoson is administered as a 0.4 mg/5mL preloaded syringe dose that is standard for all weights. Regadenoson stress tests are not affected by the presence of beta blockers, as regadenoson vasodilates via the adenosine pathway without stimulating beta adrenergic receptors.[citation needed]
Regadenoson can temporarily disrupt the integrity of the blood–brain barrier by inhibiting P-glycoprotein function.[5]
References
- ↑ "The future of pharmacologic stress: selective A2A adenosine receptor agonists". The American Journal of Cardiology 94 (2A): 33D-40D; discussion 40D-42D. July 2004. doi:10.1016/j.amjcard.2004.04.017. PMID 15261132.
- ↑ "CV Therapeutics and Astellas Announce FDA Approval for Lexiscan(TM)". Astellas Pharma US, Inc.. http://www.astellas.us/press_room/docs/FINAL_LEXISCANAPPROVAL041008.pdf.
- ↑ "Rapiscan EPAR". https://www.ema.europa.eu/en/medicines/human/EPAR/rapiscan.
- ↑ "Competitive Generic Therapy Approvals". 29 June 2023. https://www.fda.gov/drugs/generic-drugs/competitive-generic-therapy-approvals.
- ↑ "A2A adenosine receptor modulates drug efflux transporter P-glycoprotein at the blood–brain barrier". The Journal of Clinical Investigation 126 (5): 1717–33. May 2016. doi:10.1172/JCI76207. PMID 27043281.
External links
- "Regadenoson". Drug Information Portal. U.S. National Library of Medicine. https://druginfo.nlm.nih.gov/drugportal/name/regadenoson.
- "FDA warns of rare but serious risk of heart attack and death with cardiac nuclear stress test drugs Lexiscan (regadenoson) and Adenoscan (adenosine)". 12 January 2017. https://www.fda.gov/drugs/drug-safety-and-availability/fda-warns-rare-serious-risk-heart-attack-and-death-cardiac-nuclear-stress-test-drugs-lexiscan.
 |  |
